None
See all teams

The Polar Capital Global Healthcare Team

The eight-strong specialist healthcare team, set up in 2007, is led by Gareth Powell as Head of Healthcare, manager of the Healthcare Opportunities Fund. The team’s other fund managers are James Douglas (Healthcare Blue Chip Fund and the Global Healthcare Trust, with Gareth), David Pinniger (Biotechnology Fund) and Deane Donnigan (Healthcare Discovery). The team benefits from a huge amount of industry experience – including Dr Daniel Mahony in a consultancy role – with many having previously held senior industry roles, either as a research scientist, clinical specialist, in equity sales and research, or working in academic laboratories and institutes.

Total AUM (as at 31.08.2021)

2007

Established

175

Combined years of experience

8

Team members

None

Gareth Powell, CFA

Head of Healthcare
None

Daniel Mahony, PhD

Consultant
David Pinniger

David Pinniger, CFA

Fund Manager
None

Deane Donnigan, PharmD

Fund Manager
None

James Douglas, PhD

Fund Manager
None

Damiano Soardo, CFA

Investment Analyst
Tara Raveendran

Tara Raveendran, PhD

Head of Healthcare Research
None

Brett Pollard

Investment Analyst

Gareth Powell, CFA

Gareth joined Polar Capital in 2007 to set up the Healthcare team. Prior to Polar Capital, Gareth worked at Framlington, where he began his career in investment management in 1999. Soon afterwards, he joined the Healthcare Team in 2001 and helped launch the Framlington Biotech Fund, which he managed from 2004 until his departure.

Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas). As well as this, Gareth worked for the Oxford Business School and various academic laboratories including the Sir William Dunn School of Pathology and the Wolfson Institute for Biomedical Research.

  • MBiochem in Biochemistry, University of Oxford
  • CFA Charterholder
  • 23 years

Daniel Mahony, PhD

Daniel joined Polar Capital to set up the Healthcare team in 2007. From 2019 he focussed on leading healthcare strategy and business development and, since September 2021, has worked with the team on an advisory basis. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors.

Previously, Daniel worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California.

  • BA (1st Class Hons) in Biochemistry, University of OxfordPhD in Developmental Biology, University of Cambridge
  • 30 years

David Pinniger, CFA

David joined Polar Capital in August 2013 as a portfolio manager within the Healthcare team, to launch the Polar Capital Biotechnology Fund. Prior to joining Polar Capital, David was portfolio manager of the International Biotechnology Trust at SV Life Sciences.

Previously, David spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm's venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector.

  • BA (1st Class Hons) in Human Sciences, University of Oxford
  • CFA Charterholder
  • 21 years
Source & Copyright: CITYWIRE. David Pinniger has been awarded an AA rating by Citywire for his 3 year risk-adjusted performance for the period 31/08/2018 - 31/08/2021.

Deane Donnigan, PharmD

Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team, and has over 36 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia.

Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen.

  • Doctor of Pharmacy (PharmD), Clinical Pharmacy, University of Georgia in conjunction with the Medical College of Georgia
  • Board certified and licensed pharmacist, ACCP board certified pharmacotherapy specialist, IMRO qualified
  • 36 years

James Douglas, PhD

James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.

Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma.

  • PhD and BA (1st Class Hons) in Medicinal Chemistry, Newcastle University
  • ACCA diploma in financial management (DipFM)
  • 22 years

Damiano Soardo, CFA

Damiano joined the Polar Capital Healthcare team as an investment analyst in October 2020. He started at the company in 2016 as part of the Operations team before moving to the Risk team in 2019. Prior to joining Polar Capital, he worked as a technical consultant at a fintech company. Damiano has an MSc in Mathematics and Foundations of Computer Science from the University of Oxford and is a CFA charterholder.

  • MSc in Mathematics and Foundations of Computer Science, University of Oxford
  • CFA Charterholder
  • 5 years

Tara Raveendran, PhD

Tara joined Polar Capital in September 2021, as the Head of Healthcare Research within the Healthcare team. Prior to joining Polar Capital, she was the Head of Healthcare & Life Sciences Research at Shore Capital.

Previously Tara spent over 15 years working in equity research, specialising in European pharmaceuticals, biotechnology and medtech at Lehman Brothers and Jefferies. She has also worked with a number of healthcare-focused startups through her life sciences consultancy, SSquared Consulting, most recently working with the UK government’s Vaccine Taskforce.

  • BSc in Biochemistry and PhD in Structural Biology from Imperial College, London
  • PhD
  • 15 years

Brett Pollard

Brett Pollard joined the Polar Capital Healthcare team in September 2021 as an investment analyst. Prior to Polar Capital, Brett was Managing Director of Strategy and Corporate Development at Scapa plc, with responsibility for investor relations. Since 2001 he has worked across the healthcare sector and within equity capital markets as a healthcare analyst, most recently at Numis, Brett also has worked in and led financial communications, corporate development, investor relations and operations.

  • Studied cell and molecular biology at the University of St. Andrews; PhD in molecular virology.
  • PhD
  • 21 years

Funds managed by the Global Healthcare Team

i

Biotechnology Fund

Launch date31.10.2013
AUM
8Team size

Biotechnology Fund

The Fund aims to preserve capital and achieve long-term capital appreciation by investing throughout the biotechnology ecosystem, across geographies and market capitalisations.
i

Healthcare Blue Chip Fund

Launch date12.09.2014
AUM
8Team size

Healthcare Blue Chip Fund

The Fund aims to achieve long-term capital appreciation by investing in a globally diversified portfolio of healthcare companies.
i

Healthcare Discovery Fund

Launch date31.01.2020
AUM
8Team size

Healthcare Discovery Fund

The Fund aims to achieve long-term capital growth by investing in a globally diversified portfolio of healthcare companies.
i

Healthcare Opportunities Fund

Launch date30.11.2007
AUM
8Team size

Healthcare Opportunities Fund

The Fund aims to preserve capital and achieve long-term growth by investing in a globally-diversified portfolio of companies within the healthcare industry.